Products

REMI AI Discrete Detection Module
Epitel
Neurology AI
Epitel's REMI AI Discrete Detection Module is an FDA-cleared AI tool that provides automated, near real-time detection of potential electrographic seizures from wearable EEG data, enhancing brain health monitoring in both healthcare facilities and ambulatory settings.
REMI-AI Rapid Detection Module (REMI-AI RDM)
Epitel
Neurology AI
Epitel's REMI-AI Rapid Detection Module (REMI-AI RDM) is an FDA-cleared AI tool for near real-time electrographic seizure detection in non-ICU healthcare settings, utilizing wearable EEG and cloud-based analytics.

See all 2 products →

About Epitel

Epitel is a digital health company dedicated to modernizing brain health solutions, with a primary focus on improving seizure monitoring and detection. The company leverages a proprietary cloud-based wearable sensor system combined with innovative artificial intelligence (AI) technologies to offer accessible, affordable, and reliable electrographic seizure detection. Their flagship product, the REMI™ Remote EEG Monitoring System, received initial FDA clearance in 2021 for use in hospital emergency rooms and critical care units.

Further FDA clearances have expanded the REMI system’s indications for use to include ambulatory (at-home) settings and for pediatric patients as young as one year old. Epitel has also developed AI-powered modules like REMI Vigilenz™ AI for Event Detection and REMI Vigilenz™ AI For Bedside Notifications, which analyze EEG records in near real-time to identify potential electrographic seizures and provide confidence levels. These advancements aim to empower physicians, caregivers, and patients by enabling better-informed treatment decisions and improving outcomes, particularly in healthcare settings that may lack 24/7 EEG coverage or specialized technicians.

Focus Areas

Brain health seizure monitoring EEG AI neurological conditions remote patient monitoring epilepsy detection

Business Intelligence

Key InvestorsCatalyst Health Ventures (CHV), Genoa Ventures, Dexcom, OSF Ventures, Wavemaker 360, MedMountain Ventures, Salt Lake City Angels, Southwest National Pediatric Device Innovation Consortium, Angel Physicians Fund, NIH, Epilepsy Foundation
TechnologyCloud-based wearable sensor system, AI technologies, wireless EEG monitoring platform, machine learning for seizure detection
FDA Clearances5 cleared products (estimated)

What Physicians Need to Know

Brain Health & Neurological Conditions
Epitel is a digital health company focused on modernizing brain health solutions to improve seizure monitoring and detection across various neurological conditions. Their technology aims to provide accessible, affordable, and reliable brain health insights to improve quality of life and care for patients.
Seizure Monitoring & Epilepsy Detection
Epitel specializes in developing a wearable, wireless EEG monitoring platform for accurate electrographic seizure detection. Their flagship product, the REMIu2122 Remote EEG Monitoring System, is designed for both healthcare settings and ambulatory (at-home) use.
EEG Technology
Epitel's REMIu2122 system utilizes a wearable, wireless, and discreet EEG sensor that attaches to the scalp with one-piece adhesive stickers, eliminating the need for goopy gels. It features four sensors for comprehensive coverage and transmits data wirelessly to a mobile application. This simplified application allows non-specialized medical personnel to initiate EEG monitoring quickly.
Artificial Intelligence (AI)
Epitel leverages innovative AI technologies, specifically REMI Vigilenzu2122 AI for Event Detection, to analyze and mark potential electrographic seizures in EEG recordings. This AI assists with the ease and accuracy of interpretation, and the company has built a large, proprietary EEG seizure monitoring database over five years to train its robust AI algorithms.
Remote Patient Monitoring
The REMIu2122 system enables long-term, medical-grade seizure monitoring in outpatient and home environments, allowing patients to move freely and go about daily activities. This remote capability addresses the accessibility and convenience limitations of traditional EEG monitoring.
Physician Tip

Epitel's REMIu2122 system offers physicians a transformative tool for brain health monitoring. Its **wearable, wireless EEG technology** (REMIu2122 Remote EEG Monitoring System) significantly improves access to crucial EEG data, moving monitoring from large tertiary hospitals to community hospitals, emergency departments, ICUs, and even patients' homes. The **simplified application process**, requiring no specialized EEG technician, means rapid deployment and initiation of monitoring within minutes, which is vital in neurological emergencies. The **REMI Vigilenzu2122 AI for Event Detection** acts as a powerful triage tool, analyzing extended-duration EEG recordings and flagging potential electrographic seizures with high sensitivity (up to 100% for all seizures in some studies, and 86.2% event-level sensitivity in a clinical validation study), dramatically reducing the time neurologists spend reviewing uneventful data. This allows for more efficient and effective treatment decisions. Furthermore, the system is **FDA cleared for both in-facility and ambulatory use** and is **reimbursable using preexisting codes**, easing adoption into existing clinical workflows and potentially lowering overall healthcare costs by reducing hospital length of stay and unnecessary medication use.

Epitel's REMIu2122 system is built around a proprietary cloud-based wearable sensor system. The REMI Mobile application runs on qualified commercial off-the-shelf mobile computing platforms, receiving and transmitting data from REMI Sensors to the secure REMI Cloud. This data is then prepared for review on qualified EEG viewing software. The system is designed to integrate into existing physician and hospital workflows, supporting a seamless transition for seizure patients from hospital to home.

Products by Epitel

2 products in the directory

REMI AI Discrete Detection Module
Epitel
Neurology AI
Epitel's REMI AI Discrete Detection Module is an FDA-cleared AI tool that provides automated, near real-time detection of potential electrographic seizures from wearable EEG data, enhancing brain health monitoring in both healthcare facilities and ambulatory settings.
REMI-AI Rapid Detection Module (REMI-AI RDM)
Epitel
Neurology AI
Epitel's REMI-AI Rapid Detection Module (REMI-AI RDM) is an FDA-cleared AI tool for near real-time electrographic seizure detection in non-ICU healthcare settings, utilizing wearable EEG and cloud-based analytics.

What the Web Says

Epitel is a digital health company that has developed the REMI Wireless Wearable EEG system for seizure monitoring and detection, receiving FDA clearance for various age groups, including children as young as one year old. The company is generally viewed positively by employees, who highlight a mission-oriented culture, opportunities for growth, and transparent leadership. Product reviews suggest that while the REMI system offers significant advantages in terms of portability and ease of use for long-term, unobtrusive monitoring, some users on Reddit have noted drawbacks with device dependability and strap design for young children.

Overall: Positive

Strengths

  • Meaningful work and profound impact on healthcare.
  • Transparent goals and strong communication from leadership.
  • Opportunities for career growth and exposure to innovative biotech projects.
  • REMI system is wireless, easy to use, and allows patients to move freely.
  • REMI system provides accurate high-fidelity EEG recordings and rapid monitoring.
  • Automated seizure detection software improves accuracy.

Limitations

  • Occasional device battery issues and unreliability reported by some users.
  • Proprietary strap design for the REMI system can be difficult to put on for children and is not compatible with third-party straps.
  • Customer service for the product has been described as mixed, with potential delays in technical issue resolution.
  • Some features of the REMI system may be limiting for very specific needs, and advanced customization might be restricted.
  • False positive alarms and high false-negative rates have been an issue for some wearable epilepsy devices, leading to users ignoring alerts.
  • The average annual salary at Epitel Inc. is an estimation and not from factual payroll records.

Based on reviews from: G2, Glassdoor, Reddit, Indeed.com, Neurology Today, Business Wire, Epilepsia (via PMC), Epitel, Inc. (company website)

Last updated: 2026-07-18

Videos

News, demos, and interviews about Epitel.

Loading videos...

Videos load interactively. If none appear, search YouTube for Epitel →

View all on YouTube

Press & Coverage

BioUtah
Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection
Epitel announced FDA 510(k) clearances for its REMI Remote EEG Monitoring System for at-home use and REMI Vigilenz AI for Event Detection, enabling extended EEG recording in outpatient settings and AI-powered seizure identification.
2024-04
MedTech Innovator
FDA clears Epitel remote monitoring tech, AI detection platform
Epitel received FDA 510(k) clearances for its Remi remote EEG monitoring system for ambulatory use and the Remi Vigilenz AI system for identifying seizure events in EEG records.
2024-04
Business Wire
Epitel Expands AI Portfolio With A Fourth FDA 510(k) Clearance for REMI
Epitel announced its fourth FDA 510(k) clearance for REMI Vigilenz AI For Bedside Notifications, an AI/ML medical device that provides near real-time detection of potential electrographic seizures.
2024-10
Business Wire
Epitel's REMI Wireless Wearable EEG System Receives Expanded FDA Clearance for Patients as Young as One Year Old
Epitel received another FDA 510(k) clearance for its REMI Wireless EEG System, expanding its use to infants and children aged one year and older for neurological monitoring.
2025-03
PubMed (Epilepsia)
Validation of a discrete electrographic seizure detection algorithm for extended-duration, reduced-channel wearable EEG
A study validated Epitel's automated seizure detection algorithm for reduced-channel EEG, demonstrating comparable performance to current clinical software for full-montage EEG in detecting seizures across diverse patient populations.
2025-03
Genoa Ventures
Epitel Secures $12.5 Million Series A Financing for Wearable, Wireless EEG Monitoring System
Epitel closed a $12.5 million Series A financing round to support the initial pilot commercialization and further development of its wearable, wireless EEG monitoring platform for seizure detection.
2022-02
Startup Intros
Epitel: Funding, Team & Investors
Epitel has raised a total of $13.0M across one funding round, with the most recent being a $13.0M Series A in February 2022, backed by investors including Catalyst Health Ventures, Genoa Ventures, Dexcom, and OSF Ventures.
2026-07
PubMed (Frontiers in Neurology)
Wearable Reduced-Channel EEG System for Remote Seizure Monitoring
This study demonstrated that epileptologists can accurately review EEG data from Epitel's four Epilog sensors in the REMI montage to identify patients experiencing electrographic seizures, and the automated algorithm shows promise as clinical decision support software.
2021-10

Frequently Asked Questions

Epitel's primary product is the REMIu2122 Remote EEG Monitoring System, a wearable, wireless EEG platform. This system, along with REMI Vigilenzu2122 AI For Event Detection, is designed to improve seizure monitoring and detection for patients with epilepsy and other neurological conditions, both in healthcare facilities and at home.
Epitel's REMI Vigilenzu2122 AI For Event Detection analyzes EEG records to identify and mark potential electrographic seizures, categorizing them by confidence level to assist physician interpretation. The REMI system facilitates remote patient monitoring by enabling extended EEG recording in ambulatory settings, making brain health insights more accessible and empowering better treatment decisions.
Epitel's REMI Remote EEG Monitoring System (for both healthcare facility and ambulatory use) and REMI Vigilenzu2122 AI For Event Detection have received FDA 510(k) clearances. The company also prioritizes cybersecurity and has achieved SOC 2 Type 2 + HIPAA + GDPR Compliance Attestation, demonstrating its commitment to data security and privacy.
The REMI system utilizes four wireless sensors for a 10-channel EEG montage, designed for rapid and easy application by non-specialized medical personnel. Studies have shown high sensitivity and specificity in detecting electrographic seizure activity, and the system transmits data to a secure cloud for remote review by neurologists.
Epitel provides customer and technical support, with contact information available via phone and email. While specific training programs are not detailed, the system is designed for easy application, and the AI assists physicians in interpreting EEG data, suggesting a focus on user-friendly integration into clinical workflows.
Epitel, founded in 2007, has demonstrated stability through significant funding, including a $12.5 million Series A financing round in 2022 and a recent Series B deal. The company is venture-backed by several prominent investors, indicating strong financial support and potential for continued growth and market expansion.
Epitel is backed by a syndicate of venture capital firms, including Catalyst Health Ventures, Genoa Ventures, Dexcom, and OSF Ventures, among others. These partnerships suggest collaborations aimed at integrating their technology into existing healthcare workflows and expanding their reach within the medical community.

Investors

Who's funded Epitel.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.